Trial Radar IA

Discutiamo ed esploriamo gli studi clinici con TG Therapeutics come promotore principale o collaboratore.

Posso aiutarti a capire le condizioni di salute, i trattamenti o a trovare studi clinici vicini.
Il nostro strumento di ricerca supporta solo l'inglese. Per la ricerca e la discussione in altre lingue, usa Trial Radar IA sopra o seleziona i filtri per condizione medica e luogo (qui sotto).
32 studi clinici
 
Parole chiave
Ublituximab
×
 
Titolo dello studio
Stato
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis NCT07389590
Non ancora in arruolamento
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis NCT07225361
In arruolamento
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis NCT07220252
Non ancora in arruolamento
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) NCT07211633
In arruolamento
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis NCT06864936
Non ancora in arruolamento
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) (ENABLE) NCT06433752
In arruolamento
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab (ENHANCE) NCT05877963
In arruolamento
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia NCT04806035
Terminato
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL NCT04624633
Attivo, non in arruolamentoRisultati pubblicati
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy NCT04149821
TerminatoRisultati pubblicati
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis NCT04130997
Attivo, non in arruolamento
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax NCT04016805
TerminatoRisultati pubblicati
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma NCT03828448
TerminatoRisultati pubblicati
Study of TG-1801 in Subjects With B-Cell Lymphoma NCT03804996
Completato
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) NCT03801525
TerminatoRisultati pubblicati
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma NCT03778073
Terminato
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies NCT03671590
Terminato
An Extension of the TG1101-RMS201 Trial NCT03381170
Completato
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL NCT03379051
Terminato
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) NCT03277261
CompletatoRisultati pubblicati
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) (ULTIMATE II) NCT03277248
CompletatoRisultati pubblicati
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials NCT03207256
Terminato
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL) NCT02793583
Terminato
Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis NCT02738775
CompletatoRisultati pubblicati
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 NCT02656303
TerminatoRisultati pubblicati
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (UNITY-CLL) NCT02612311
TerminatoRisultati pubblicati
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation NCT02535286
Completato
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) (GENUINE) NCT02301156
CompletatoRisultati pubblicati
Ublituximab + Ibrutinib in Select B-cell Malignancies NCT02013128
Completato
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies NCT02006485
Completato
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies NCT01744912
Terminato
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT01647971
Completato